| JOURNAL OF CONTROLLED RELEASE | 卷:163 |
| Improvement of drug safety by the use of lipid-based nanocarriers | |
| Article; Proceedings Paper | |
| Onyuksel, Hayat1,2  | |
| [1] Univ Illinois, Coll Pharm, Dept Biopharmaceut Sci, Chicago, IL 60612 USA | |
| [2] Univ Illinois, Dept Bioengn, Chicago, IL 60612 USA | |
| 关键词: Lipid nanocarriers; Drug safety; Micelles; Liposomes; Solid lipid nanoparticle; | |
| DOI : 10.1016/j.jconrel.2012.06.002 | |
| 来源: Elsevier | |
PDF
|
|
【 摘 要 】
Drug toxicity is an important factor that contributes significantly to adverse drug events in current healthcare practice. Application of lipid-based nanocarriers in drug formulation is one approach to improve drug safety. Lipid-based delivery systems include micelles, liposomes, solid lipid nanoparticles, nanoemulsions and nanosuspensions. These carriers are generally composed of physiological lipids well tolerated by human body. Delivery of water-insoluble drugs in these formulations increases their solubility and stability in aqueous media and eliminates the need for toxic co-solvents or pH adjustment to solubilize hydrophobic drugs. Association or encapsulation of peptides/proteins within lipid-based carriers protects the labile biologics against enzymatic degradation, hence reducing the therapeutic dose required and risk of dose-dependent toxicity. Most importantly, lipid-based nanocarriers alter the pharmacokinetics and biodistribution of drugs through passive and active targeting, leading to increased drug accumulation at target sites while significantly decreasing non-specific distribution to other tissues. Furthermore, surface modification of these nanocarriers reduces immunogenicity of drug-carrier complexes, imparts stealth by preventing opsonization and removal by phagocytes and minimizes interaction with circulating blood components. In view of heightening attention on drug safety in patient treatment, lipid-based nanocarrier is therefore an important and promising option for formulation of pharmaceutical products to improve treatment safety and efficacy. (C) 2012 Elsevier B.V. All rights reserved.
【 授权许可】
Free
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| 10_1016_j_jconrel_2012_06_002.pdf | 660KB |
PDF